PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för ASP-3026. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

16 hits

Bibliografisk träff 2020-12-17

Safety and Antitumor Activity of Repeated ASP3026 Administration in Japanese Patients with Solid Tumors: A Phase I Study.

Ono A, Murakami H, Seto T, Shimizu T, Watanabe S, Takeshita S, Takeda K, Toyoshima J, Nagase I, Bahceci E, Morishita M, Morita S, Fukuoka M, Nakagawa K.

Drugs R D · research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.1007/s40268-020-00331-2

Bibliografisk träff 2020-11-01

Inhibition of Plasmodium falciparum Lysyl-tRNA synthetase via an anaplastic lymphoma kinase inhibitor.

Zhou J, Huang Z, Zheng L, Hei Z, Wang Z, Yu B, Jiang L, Wang J, Fang P.

Nucleic Acids Res · research support, non-u.s. gov't; research-article; journal article · DOI 10.1093/nar/gkaa862

Bibliografisk träff 2019-07-24

Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK<sup>+</sup> T-cell lymphoma.

George B, George SK, Shi W, Haque A, Shi P, Eskandari G, Axelson M, Larsson O, Kaseb AO, Amin HM.

J Hematol Oncol · research-article; journal article; research support, n.i.h., extramural · DOI 10.1186/s13045-019-0768-8

Bibliografisk träff 2019-06-08

Activation of IGF-1R pathway and NPM-ALK G1269A mutation confer resistance to crizotinib treatment in NPM-ALK positive lymphoma.

Li Y, Wang K, Song N, Hou K, Che X, Zhou Y, Liu Y, Zhang J.

Invest New Drugs · research support, non-u.s. gov't; journal article · DOI 10.1007/s10637-019-00802-7

Bibliografisk träff 2018-01-01

Discovery of N-{2-Methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}-N'-[2-(propane-2-sulfonyl)phenyl]-1,3,5-triazine-2,4-diamine (ASP3026), a Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor.

Iikubo K, Kondoh Y, Shimada I, Matsuya T, Mori K, Ueno Y, Okada M.

Chem Pharm Bull (Tokyo) · journal article · DOI 10.1248/cpb.c17-00784

Bibliografisk träff 2017-09-20

Inhibition of Erythrocyte Cell Membrane Scrambling by ASP3026.

Al Mamun Bhuyan A, Bissinger R, Cao H, Lang F.

Cell Physiol Biochem · journal article · DOI 10.1159/000480477

Bibliografisk träff 2016-07-05

Drastic initial response and subsequent response to two ALK inhibitors in a patient with a highly aggressive ALK-rearranged inflammatory myofibroblastic tumor arising in the pleural cavity.

Ono A, Murakami H, Serizawa M, Wakuda K, Kenmotsu H, Naito T, Taira T, Koh Y, Ohde Y, Nakajima T, Endo M, Takahashi T.

Lung Cancer · journal article; case reports · DOI 10.1016/j.lungcan.2016.07.002

Bibliografisk träff 2016-03-10

Mouse models for ROS1-fusion-positive lung cancers and their application to the analysis of multikinase inhibitor efficiency.

Inoue M, Toki H, Matsui J, Togashi Y, Dobashi A, Fukumura R, Gondo Y, Minowa O, Tanaka N, Mori S, Takeuchi K, Noda T.

Carcinogenesis · research support, non-u.s. gov't; journal article · DOI 10.1093/carcin/bgw028

Bibliografisk träff 2016-03-10

First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors.

Li T, LoRusso P, Maitland ML, Ou SH, Bahceci E, Ball HA, Park JW, Yuen G, Tolcher A.

J Hematol Oncol · research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.1186/s13045-016-0254-5

Bibliografisk träff 2015-07-01

Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer or Other Tumors.

Nishio M, Murakami H, Horiike A, Takahashi T, Hirai F, Suenaga N, Tajima T, Tokushige K, Ishii M, Boral A, Robson M, Seto T.

J Thorac Oncol · research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.1097/jto.0000000000000566

Bibliografisk träff 2015-03-01

NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.

Mologni L, Ceccon M, Pirola A, Chiriano G, Piazza R, Scapozza L, Gambacorti-Passerini C.

Oncotarget · research support, non-u.s. gov't; research-article; journal article · DOI 10.18632/oncotarget.3122

Bibliografisk träff 2015-02-27

Novel ALK inhibitors in clinical use and development.

Iragavarapu C, Mustafa M, Akinleye A, Furqan M, Mittal V, Cang S, Liu D.

J Hematol Oncol · research support, non-u.s. gov't; research-article; review; journal article · DOI 10.1186/s13045-015-0122-8

Bibliografisk träff 2015-02-26

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.

Fontana D, Ceccon M, Gambacorti-Passerini C, Mologni L.

Cancer Med · research support, non-u.s. gov't; research-article; journal article · DOI 10.1002/cam4.413

Bibliografisk träff 2015-01-01

Characterization and Thermodynamic Stability of Polymorphs of Di(arylamino) Aryl Compound ASP3026.

Takeguchi K, Hirakura Y, Yamazaki K, Shimada I, Ieda S, Okada M, Takiyama H.

Chem Pharm Bull (Tokyo) · research support, non-u.s. gov't; journal article · DOI 10.1248/cpb.c14-00774

Bibliografisk träff 2014-07-01

The ALK inhibitor ASP3026 eradicates NPM-ALK⁺ T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model.

George SK, Vishwamitra D, Manshouri R, Shi P, Amin HM.

Oncotarget · research-article; journal article; research support, n.i.h., extramural · DOI 10.18632/oncotarget.2170

Bibliografisk träff 2014-01-13

The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice.

Mori M, Ueno Y, Konagai S, Fushiki H, Shimada I, Kondoh Y, Saito R, Mori K, Shindou N, Soga T, Sakagami H, Furutani T, Doihara H, Kudoh M, Kuromitsu S.

Mol Cancer Ther · research support, non-u.s. gov't; journal article · DOI 10.1158/1535-7163.mct-13-0395